TCR² Therapeutics to Present at the H.C. Wainwright BioConnect Conference
January 05 2022 - 6:45AM
TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell
therapy company with a pipeline of novel T cell therapies for
cancer patients suffering from solid tumors, today announced that
Garry Menzel, President and Chief Executive Officer of
TCR² Therapeutics, will present an update on Company progress
at the H.C. Wainwright BioConnect Conference on Monday, January
10th at 7:00AM E.T. using a virtual platform.
A live webcast of the presentation will be
available on the Investors page of the Company’s website at
www.investors.tcr2.com. An archived replay will be available for at
least 30 days following the presentation.
About
TCR² Therapeutics
TCR² Therapeutics Inc. is a clinical-stage
cell therapy company developing a pipeline of novel T cell
therapies for cancer patients suffering from solid tumors. The
company is focused on the discovery and development of product
candidates against novel and complex targets utilizing
its proprietary T cell receptor (TCR) Fusion Construct
T cells (TRuC®-T cells). The TRuC platform is designed to
specifically recognize and kill cancer cells by harnessing
signaling from the entire TCR, independent of human leukocyte
antigens (HLA). For more information about TCR², please
visit www.tcr2.com.
Investor and Media Contacts:
TCR² Therapeutics
Carl MauchDirector, Investor Relations and Corporate
Communications(617) 949-5667carl.mauch@tcr2.com
TCR2 Therapeutics (NASDAQ:TCRR)
Historical Stock Chart
From Jun 2024 to Jul 2024
TCR2 Therapeutics (NASDAQ:TCRR)
Historical Stock Chart
From Jul 2023 to Jul 2024